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Abstract
Background: In several autoimmune diseases, including multiple sclerosis (MS), a compromised regulatory T cell (Treg)
function is believed to be critically involved in the disease process. In vitro, the biologically active metabolite of vitamin D
has been shown to promote Treg development. A poor vitamin D status has been linked with MS incidence and MS disease
activity. In the present study, we assess a potential in vivo correlation between vitamin D status and Treg function in
relapsing remitting MS (RRMS) patients.
Methodology/Principal Findings: Serum levels of 25-hydroxyvitamin D (25(OH)D) were measured in 29 RRMS patients. The
number of circulating Tregs was assessed by flow-cytometry, and their functionality was tested in vitro in a CFSE-based
proliferation suppression assay. Additionally, the intracellular cytokine profile of T helper cells was determined directly ex-
vivo by flow-cytometry. Serum levels of 25(OH)D correlated positively with the ability of Tregs to suppress T cell
proliferation (R=0.590, P=0.002). No correlation between 25(OH)D levels and the number of Tregs was found. The IFN-c/IL-
4 ratio (Th1/Th2-balance) was more directed towards IL-4 in patients with favourable 25(OH)D levels (R=20.435, P=0.023).
Conclusions/Significance: These results show an association of high 25(OH)D levels with an improved Treg function, and
with skewing of the Th1/Th2 balance towards Th2. These findings suggest that vitamin D is an important promoter of T cell
regulation in vivo in MS patients. It is tempting to speculate that our results may not only hold for MS, but also for other
autoimmune diseases. Future intervention studies will show whether modulation of vitamin D status results in modulation
of the T cell response and subsequent amelioration of disease activity.
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Introduction
Multiple Sclerosis (MS) is a disabling, chronic inflammatory
disease of the central nervous system (CNS). Although some
patients experience progression of disability from the first
symptoms onwards, the disease is at its onset mostly characterised
by repetitive sub-acute deteriorations of symptoms with remissions
afterwards, i.e. relapsing remitting MS (RRMS). After several
years, sustained and progressive disability often occurs and the
disease becomes secondary progressive [1].
Although the pathophysiological process in MS is not yet fully
elucidated, T cell mediated inflammation within the CNS plays an
important role. Auto-reactive T cells move through the blood
brain barrier, and contribute to local inflammation of the CNS
[2]. Historically, these auto-reactive T cells were believed to
comprise predominantly interferon gamma (IFN-c) producing T
helper 1 (Th1) cells. More recently interleukin-17 (IL-17)
producing Th17 cells have been argued to be important
pathogenic T cells in MS [3,4]. In a healthy T cell compartment,
regulatory T cells (Treg) regulate the quantity and quality of the
immune response, and prevent auto-reactive T cell responses, and
hereby autoimmune diseases [5]. Although the number of Tregs is
not decreased, their capability to suppress polyclonal or antigen-
specific proliferation of T cells in vitro has been shown to be
compromised in MS patients [6–8].
Experimental studies showed that the biologically active meta-
bolite of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D), is
able to skew the T cell compartment into a more anti-
inflammatory and regulated state, with inhibition of Th1 and
Th17 cells and promotion of Th2 and Treg cells [9,10].
Interestingly, in the experimental autoimmune encephalomyelitis
(EAE) animal model of MS, treatment with vitamin D prevented,
and even cured, the disease [11]. These findings suggest a potential
role for vitamin D in MS, as has been investigated in several
epidemiological studies. Near the equator, where vitamin D
photosynthesis is optimal, MS incidence is low [12]. Furthermore,
increased sun exposition and a good vitamin D status in childhood
and adolescence, reflected by the serum values of 25-hydro-
xyvitamin D (25(OH)D) [13], have been associated with a
decreased risk for developing MS [14–16]. An increased activity
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D status [17–19]. Since vitamin D modulates the immune
response in vitro and in animal models, it is highly interesting to
assess whether this modulation can also be found in vivo in MS
patients. This could be, beside regulation of the transcription of
MS-associated alleles [20], an important driver of the associations
between vitamin D status and MS. At present, however, no
published studies assessed the potential relationship between
serum levels of 25(OH)D and the T cell compartment in MS.
In the present study, we assess whether vitamin D status is
correlated with the in vivo composition and function of the T cell
compartment in MS patients. Since in RRMS patients with a short
disease duration disease pathophysiology has been argued to be
predominantly inflammatory [1] and Treg function has been
shown to be particularly compromised [7], we assess a potential
anti-inflammatory and in particular Treg-promoting effect of
vitamin D, as being related to vitamin D status, in these patients.
Materials and Methods
Subjects
We included in this study 29 Caucasian subjects, by
approaching consecutive patients matching the inclusion criteria,
who visited the outpatient clinic of our MS centre. All subjects had
RRMS according to the revised McDonald criteria [21], with a
disease duration of ,5 years since the first to MS attributable
symptoms. Both patients treated with interferon beta 1a or 1b, and
patients untreated with immune modulation were included.
Exclusion criteria were: no clinically definite phenotype, use of
other immune modulation than interferon beta 1a or 1b,
occurrence of a relapse ,6 weeks before blood collection, recent
start (,
1/2 year) of vitamin D supplementation. The character-
istics of the patients are described in Table 1.
Ethical statement
Written informed consent was acquired from all subjects
participating in this study, according to the declaration of Helsinki.
The study was reviewed and approved by both the regional ethical
committee on human research ‘Atrium-Orbis-Zuyd’, and the
institutional ethical committee ‘Local Advisory board on Scientific
Research’.
Vitamin D assays
Blood withdrawal was performed in the period from September
2008 until February 2009. The cells for the cellular assays and the
serum for vitamin D measurement were retrieved at the same
time, and cellular assays were performed on the day of blood
collection. The collected serum was immediately shielded from
direct light and stored at 220uC. At the end of the study, all
samples were analysed simultaneously. The serum values of
25(OH)D were measured with a commercially available radio-
immuno assay (Immunodiagnostic Systems, Boldon, UK) [18].
Cell culture reagents
Cells were cultured in RPMI glutamax medium (Gibco
Invitrogen, Breda, The Netherlands) supplemented with 10%
Foetal Calf Serum (Greiner Bio-One, Alphen a/d Rijn, The
Netherlands), 1% non-essential amino acids (Gibco Invitrogen),
1% sodium pyruvate (Gibco Invitrogen) and 2% penicillin-
streptomycin (Gibco Invitrogen) in U-bottom 96-wells plates.
Cell purification
Cell isolation was performed as described before, with minor
modifications [22]. PBMC were isolated by Ficoll gradient
centrifugation (Histopaque; Sigma Aldrich, Zwijndrecht, The
Netherlands). CD4
+ T cells were selectively isolated with
RosetteSep (Stem Cell Technologies, Grenoble, France). Approx-
imately 20–30610
6 CD4
+ T cells were incubated at 4uC for 30
minutes with anti-CD4-APC (BD Biosciences, Breda, The
Netherlands), anti-CD25-PE (BD Biosciences) and anti-CD127-
FITC (BD Biosciences). Human CD4
+CD25
+CD127
2 Tregs
[23,24] and CD4
+CD25
2 responder T cells (Tresps) were sorted
on a FacsAria
TM (BD Biosciences) cell sorter (Figure 1A). The
mean purity of the sorted populations was 97.51% (SD 0.81) for
the Tregs and 97.45% (SD 1.65) for the Tresps. Accessory cells
were obtained by irradiating autologous PBMC with 66.2 gray.
Proliferation assay
The CFSE-based proliferation suppression assay was adapted
from Venken et al. [22]. In short, the freshly isolated CD4
+CD25
2
Tresps were labelled with carboxy fluorescein diacetate succini-
midyl ester (CFSE; Molecular Probes Invitrogen, Breda, The
Netherlands). In a U-bottom 96-wells plate, 2610
5 Tresps were
stimulated with soluble anti-CD3 (2.0 pg/mL, WT32 IgG2a
monoclonal antibody, kindly provided by dr. W Tax, Radboud
University Nijmegen Medical Centre, Nijmegen, The Nether-
lands) in the presence of 2610
5 irradiated accessory cells. Tresps
were co-cultured for 5 days with varying amounts of Tregs (Treg/
Tresp ratios 0/1, 0.25/1, 0.5/1, 1/1 or 2/1). All conditions were
performed in triplo in a final volume of 200 mL. After culture, the
cells were stained with anti-CD4-APC and 7AAD (BD Bioscienc-
es), and the CFSE signal of cells in the CD4
+7AAD
2 lymphogate
was analysed by Flow Cytometry on a FacsCalibur
TM flowcyt-
ometer (BD Biosciences). Data were analysed with CellQuest
software (BD Biosciences). The amount of proliferation achieved
in the 0/1 ratio was set at 0% suppression. The mean relative
amount of suppression in the other ratios was calculated. By linear
interpolation, the Treg/Tresp ratio at which 50% suppression of
proliferation was achieved (ED50) was calculated.
T cell phenotyping
Tregs were defined as CD25
+FoxP3
+ CD4
+ T cells [25,26] and
as CD25
+CD127
2 CD4
+T cells [23,24]. For determining the
proportion of Tregs, PBMC were stained with anti-CD3-PerCP
(BD Biosciences), anti-CD4-APC, anti-CD4-FITC (BD Bioscienc-
es), anti-CD25-PE, anti-CD127-FITC or anti-FoxP3-APC (E-
Bioscience, San Diego, USA), and analysed on a FacsCalibur
TM
flowcytometer [27]. The absolute number of lymphocytes was
determined with a haematological cell counter (Beckman Coulter,
Woerden, The Netherlands).
Table 1. Patient characteristics.
Median/N (%) Range [min–max]
Male/Female (N) 10 (34%)/19 (66%)
Age (years) 39.23 [22.61–58.63]
Duration MS (years) 3.48 [0.69–4.89]
Relapse Rate (N/year) 0.00 [0.00–3.00]
Relapse free (years) 1.04 [0.10–3.91]
EDSS* score (points) 2.00 [0.00–6.00]
Interferon beta treated (N) 25 (86%)
*Expanded Disability Status Scale.
doi:10.1371/journal.pone.0006635.t001
Vitamin D and Tregs in MS
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6635T helper cell subsets were determined by assessing the
intracellular cytokine pattern of CD3
+CD8
2 lymphocytes, which
are further referred to as CD4
+ T cells, by flowcytometry [27].
PBMC were stimulated for 5 hours with calcium ionomycine
(Sigma Aldrich), phorbol 12-myristate 13-acetate (PMA; Sigma
Aldrich) and monensin (BD Biosciences). Cells were stained intra-
cellularly with anti-IL-4-PE (BD Biosciences), anti-IFN-c-FITC
(BD Biosciences), anti-IL-17-PE (E-Bioscience) and anti-IL-10-PE
(E-Bioscience), and extra-cellularly with anti-CD3-PerCP and
anti-CD8-APC.
Statistics
Statistical analysis was conducted with Statistical Package for
Social Sciences version 15.0 software (SPSS inc., Chicago IL,
USA) and figures were constructed with GraphPad Prism 5
software (GraphPad Software inc., La Jolla CA, USA). Of
continuous variables, the median value and corresponding range
(min–max) are provided. When normally distributed (Shapiro-
Wilk test P.0.05), a linear relationship between two continuous
variables was tested with the Pearson correlation coefficient
(Pearson R). Abnormally distributed variables were Log-trans-
formed. In case of persistent abnormal distribution, the Spearman
correlation coefficient (Spearman R) was determined. A P
value,0.05 was considered statistically significant.
Results
Serum 25(OH)D levels
We determined the serum levels of 25(OH)D, the vitamin D
metabolite which is accepted to reflect vitamin D status best [13].
The median serum 25(OH)D level was 54 nmol/L (19–133).
Suppressive capacity of Tregs correlates positively with
25(OH)D levels
To evaluate Treg suppressive capacity, we conducted an in vitro
CFSE-based proliferation suppression assay (Figure 1B). Of 4
patients, not enough cells were retrieved to start the assay. In all
other individual patients, Tregs suppressed proliferation of T
responder cells in a dose-dependent manner. There was no
apparent difference in Treg suppression between Beta Interferon
treated and untreated patients (Figure 1B). The median Treg/
Tresp ratio at 50% suppression of proliferation (ED50) was 0.82
(0.16 - 1.96). Serum 25(OH)D levels correlated negatively with
ED50 (Spearman R=20.590, P=0.002) (Figure 2A). This
correlation was reflected by the positive correlation between
vitamin D status and the amount of suppression in the individual
Treg/Tresp ratios (Figure 2B–E).
Number of circulating Tregs does not correlate with
25(OH)D levels
Next, we evaluated the absolute and relative number of Tregs in
the circulation (Figure 3). Regulatory cells within the CD4
+ T cell
compartment were defined as CD25
+CD127
2 and CD25
+FoxP3
+
cells. The median percentage of CD25+FoxP3+ Tregs in the
CD4+ T cell compartment was 5.63% (2.67–15.81) (absolute
number 9.616107 c/L (4.65–25.41)). The median percentage of
CD25+CD1272 Tregs was 6.56% (2.93–12.32) (absolute
10.326107 c/L (4.44–24.14)). A strong positive correlation was
observed between the numbers of CD25
+CD27
2 and
CD25
+FoxP3
+ CD4
+Tregs (R=0.826, P,0.001). Serum levels
of 25(OH)D were not correlated with the relative and absolute
number of Tregs (Figure 4).
The Th1/Th2 balance correlates negatively with 25(OH)D
levels
CD4
+ T cells were classified as Th1, Th2 or Th17 by assessing
their intracellular cytokine profile (IFN- c, IL-4 and IL-17, resp.)
(Figure 5A). We also assessed the percentage of CD4
+ T cells
producing the regulatory cytokine IL-10 [9]. The median
percentage of IFN-c
+ cells within the CD4
+ T cell compartment
was 12.11% (2.60 - 26.18), of IL-4
+ cells 2.07% (0.90–4.93), of IL-
17
+ cells 0.92% (0.31–2.35), and of IL-10
+ cells 0.83% (0.43–1.45).
No significant correlations between serum 25(OH)D levels and the
individual percentages of T helper cell subsets were found,
although there was a trend towards a negative correlation with the
percentage of IFN-c
+CD4
+ T cells (Pearson R=20.336
P=0.060). The balance between Th1 and Th2 is used to indicate
a more pro- or anti-inflammatory composition of the T cell
compartment [4]. This balance is described by the ratio of IFN-c
+
and IL-4
+ CD4
+ T cells. The IFN-c/IL-4 ratio correlated
negatively with serum 25(OH)D levels (Pearson R=20.435
P=0.023) (Figure 5B).
Figure 1. Results proliferation suppression assay. (A) Represen-
tative dot-plot of the sorting protocol. CD25
+CD127
2 cells within the
CD4
+ lymphogate were sorted as Tregs, CD25
2 cells were sorted as
Tresps. (B) The percentages of suppression which were achieved for the
respective Treg/Tresp ratios of the individual patients are shown. The
Treg/Tresp ratio at which 50% inhibition of proliferation was achieved is
defined as ED50 of suppression. The distribution of ED50 is shown in
the rightmost column. The lines show the median values. The closed
dots represent the Beta Interferon-treated patients, the open dots the
untreated patients.
doi:10.1371/journal.pone.0006635.g001
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D status or T cell parameters
Neither vitamin D status, nor T cell parameters as Treg
function or T cell phenotype did correlate with measures of MS
disease activity as described in table 1 (data not shown).
Discussion
Vitamin D status has been linked with MS either in large
epidemiological studies or in experimental in vitro and animal
studies. This is the first study to investigate the correlation between
vitamin D status and the composition of the T cell compartment
Figure 2. Correlation between Treg suppressive function and serum 25(OH)D levels. (A) The correlation between ED50 and serum
25(OH)D levels. (B–E) Correlation between inhibition of suppression and 25(OH)D levels for the individual Treg/Tresp ratios. The Spearman correlation
coefficient is shown. The regression line illustrates the direction of the association. The closed dots represent the Beta Interferon-treated patients, the
open dots the untreated patients.
doi:10.1371/journal.pone.0006635.g002
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shows that serum 25(OH)D levels correlate positively with the
ability of CD4
+CD25
+CD127
2 Tregs to suppress proliferation of
Tresp cells. The absolute and relative Treg numbers in the
circulation were not correlated with vitamin D status. Although we
did not observe a significant association between 25(OH)D levels
and the individual percentages of CD4
+ T helper cell subsets, the
decreasing IFN-c/IL-4 ratio reflected a skewing of the Th1/Th2-
balance towards a more Th2 phenotype in patients with higher
serum 25(OH)D levels. Altogether, this data indicates that high
serum 25(OH)D levels are associated with a less inflammatory and
better regulated T cell compartment in MS.
In our data, we found no association between vitamin D status
and disease severity and activity of MS. This is in contrast with
earlier observations [17–19]. However, since we measured patients
in the period from September until February, the seasonal
fluctuation of vitamin D status is likely to confound these
associations [28]. In contrast to the MS activity variables, this
seems not critical for the correlation with the T cell tests: the data
obtained reflects the status of the T cell compartment at the
moment of blood collection. Hereby, several studies have shown a
seasonal fluctuation of immunological parameters in MS patients
comparable to the fluctuation of serum 25(OH)D levels [29,30].
In a previous study, CD4
+CD25
high Tregs of RRMS patients
achieved only about 40% suppression in a 1:1 Treg/Tresp ratio as
measured in a
3H-Thymidine assay [8]. A later study confirmed a
mean suppression of 40% in untreated RRMS patients, and of
50% in Beta interferon users [7]. Our RRMS patients reached in
the 1:1 ratio a mean suppression of 60% (20–90). Beta Interferon
treatment has been shown to promote Treg function [31].
Therefore, the fact that most of our patients were treated with
Beta Interferon might have contributed to this substantially more
favourable suppression. Additionally, we included the a-chain of
the IL-7 receptor (CD127), which has been shown to be
specifically absent on CD4
+CD25
+FoxP3
+ Tregs, in our sorting
protocol to define Tregs [23,24]. Therefore, the sorted population
of CD4
+CD25
+CD127
2 Tregs may comprise a more pure Treg
fraction, compared to CD4
+CD25
high sorted T cells alone [32].
Our data shows that in RRMS patients with a short disease
duration, in which Treg function has been shown to be
particularly compromised [7], Treg suppressor function correlates
positively with serum 25(OH)D levels. The relationship between
Treg function and 25(OH)D levels is likely to contribute to the
inter-individual variation of Treg suppressive function in MS
cohorts in other studies [6–8]. However, we could not find an
association of serum vitamin D values with the number of
CD4
+CD25
+FoxP3
+ or CD4
+CD25
+CD127
2 Tregs in the
circulation. This discrepancy between the impaired number and
function of Tregs has been shown in other studies on Tregs in MS
and other autoimmune diseases [33]. However, the underlying
mechanism is not know. Interestingly, a recent publication showed
a negative correlation between the percentage of FoxP3
+ Tregs
Figure 3. Relative and absolute number of circulating Tregs. Within the CD3
+CD4
+ lymphogate, Tregs were defined as either being (A)
CD25
+FoxP3
+ or being (B) CD25
+CD127
2. (C) The percentages of Tregs within the CD4
+ T cell compartment. (D) Absolute number of circulating Tregs.
The lines indicate the median values.
doi:10.1371/journal.pone.0006635.g003
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PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6635Figure 4. Correlation of the number of circulating Tregs with serum 25(OH)D levels. (A–D) Correlation of relative and absolute number of
Tregs with 25(OH)D levels. The Pearson correlation coefficient and corresponding regression line are shown.
doi:10.1371/journal.pone.0006635.g004
Figure 5. Correlation of T helper cell subsets with serum 25(OH)D levels. (A) The percentages of IFN-c
+, IL-4
+, IL-17
+ and IL-10
+ CD4
+ T cells.
The lines show the median values. (B) The correlation between IFN-c/IL-4 ratio and serum 25(OH)D levels. The Pearson correlation coefficient and
corresponding regression line are shown.
doi:10.1371/journal.pone.0006635.g005
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status [34]. However, the heterogeneous study population
considering race and disease duration, and the use of linear
regression models to analyse non-equally distributed parameters in
a limited sample size, require careful interpretation of these results.
The discrepancy with our data not showing a comparable
correlation, might be attributable to these methodological
differences.
Additionally, we found a negative correlation between serum
25(OH)D levels and the IFN-c/IL-4 ratio. This ratio is commonly
used to describe the balance in the immune system between pro-
inflammatory IFN-c
+ Th1 cells and anti-inflammatory IL-4
+ Th2
cells [4]. Our data suggests that, in patients with relatively high
25(OH)D-levels, the balance between Th1 and Th2 is more
skewed in the direction of Th2. Interestingly, in vitro research also
suggested that vitamin D skews the T cell compartment from a
Th1 towards a Th2 phenotype [9,10]. Therefore, high 25(OH)D
D levels appear to be associated with a less-pro-inflammatory T-
cell compartment in MS patients.
In conclusion, we have shown that serum 25(OH)D levels are
associated with the suppressive function of Tregs and the
composition of the T cell compartment in MS patients. These
findings further support the hypothesis that vitamin D is an
important promoter of T cell regulation in MS. Since in RRMS
patients the Treg compartment has been shown to be compro-
mised, our findings provide additional arguments to maintain a
healthy vitamin D status in these patients. Also other autoimmune
diseases have been associated with both low vitamin D levels, and
a reduced regulatory T cell function [33,35]. Whether a poor
vitamin D status correlates in healthy populations with a reduced
Treg function and potentially a subsequently increased risk for
developing autoimmune diseases, remains to be established.
Altogether, it is tempting to speculate about the potential
therapeutic effect of vitamin D supplementation in autoimmune
diseases. Previously, it was demonstrated that therapy with Beta
Interferon in MS results in a promotion of regulatory T cell
function [31] and a decrease of relapse rate [36]. Since we
observed an additional effect of 25(OH)D levels in Beta Interferon
users, this might provide a rationale for add-on therapy with
vitamin D during Beta Interferon therapy in MS. Randomized
clinical trials should assess an additional role of vitamin D
treatment on the T cell compartment and more importantly on
disease activity of MS.
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